AU2016355113A1 - Abuse resistant transdermal delivery devices and compositions comprising an opioid agonist and a non-transdermally delivered N-oxide derivative of an opioid antagonist for the treatment of pain - Google Patents

Abuse resistant transdermal delivery devices and compositions comprising an opioid agonist and a non-transdermally delivered N-oxide derivative of an opioid antagonist for the treatment of pain Download PDF

Info

Publication number
AU2016355113A1
AU2016355113A1 AU2016355113A AU2016355113A AU2016355113A1 AU 2016355113 A1 AU2016355113 A1 AU 2016355113A1 AU 2016355113 A AU2016355113 A AU 2016355113A AU 2016355113 A AU2016355113 A AU 2016355113A AU 2016355113 A1 AU2016355113 A1 AU 2016355113A1
Authority
AU
Australia
Prior art keywords
oxide derivative
pct
opioid
oxide
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2016355113A
Other languages
English (en)
Inventor
Steve Whitelock
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Euro Celtique SA
Original Assignee
Euro Celtique SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Euro Celtique SA filed Critical Euro Celtique SA
Publication of AU2016355113A1 publication Critical patent/AU2016355113A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A61K9/7061—Polyacrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
AU2016355113A 2015-11-19 2016-11-18 Abuse resistant transdermal delivery devices and compositions comprising an opioid agonist and a non-transdermally delivered N-oxide derivative of an opioid antagonist for the treatment of pain Abandoned AU2016355113A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1520390.4 2015-11-19
GBGB1520390.4A GB201520390D0 (en) 2015-11-19 2015-11-19 Composition
PCT/GB2016/053600 WO2017085502A1 (en) 2015-11-19 2016-11-18 Abuse resistant transdermal delivery devices and compositions comprising an opioid agonist and a non-transdermally delivered n-oxide derivative of an opioid antagonist for the treatment of pain

Publications (1)

Publication Number Publication Date
AU2016355113A1 true AU2016355113A1 (en) 2018-05-24

Family

ID=55133015

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2016355113A Abandoned AU2016355113A1 (en) 2015-11-19 2016-11-18 Abuse resistant transdermal delivery devices and compositions comprising an opioid agonist and a non-transdermally delivered N-oxide derivative of an opioid antagonist for the treatment of pain

Country Status (14)

Country Link
US (1) US20180344726A1 (enExample)
EP (1) EP3377048B1 (enExample)
JP (1) JP2018534319A (enExample)
KR (1) KR20180074797A (enExample)
CN (1) CN108601747A (enExample)
AU (1) AU2016355113A1 (enExample)
BR (1) BR112018009886A2 (enExample)
CA (1) CA3005775A1 (enExample)
ES (1) ES2799516T3 (enExample)
GB (1) GB201520390D0 (enExample)
IL (1) IL259457A (enExample)
MX (1) MX2018006157A (enExample)
SG (1) SG11201803913RA (enExample)
WO (1) WO2017085502A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20210078515A (ko) * 2018-10-18 2021-06-28 아비어, 인크. 만성 신장 질환-연관 소양증의 치료 방법 및 장치

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4722928A (en) * 1985-12-02 1988-02-02 E. I. Du Pont De Nemours And Company N-oxide prodrug derivatives of 3-hydroxy morphinans and partial morphinans having improved oral bioavailability, pharmaceutical compositions, and processes
SI2283842T1 (sl) * 2000-02-08 2015-07-31 Euro-Celtique S.A. Oralne formulacije opioidnih agonistov, varne pred zlorabo
GB0026137D0 (en) * 2000-10-25 2000-12-13 Euro Celtique Sa Transdermal dosage form
US20040033253A1 (en) * 2002-02-19 2004-02-19 Ihor Shevchuk Acyl opioid antagonists
JP4949625B2 (ja) * 2002-06-10 2012-06-13 ユーロ−セルティーク エス．エイ． 経皮送達デバイスに含有された活性薬剤の誤用を防止する、経皮送達デバイスの廃棄システム
EP1718258B1 (en) * 2004-02-23 2009-03-25 Euro-Celtique S.A. Abuse resistance opioid transdermal delivery device
US20080234306A1 (en) * 2006-11-22 2008-09-25 Progenics Pharmaceuticals, Inc. N-Oxides of 4,5-Epoxy-Morphinanium Analogs
WO2009067275A1 (en) * 2007-11-21 2009-05-28 Progenics Pharmaceuticals, Inc N-oxides of 4,5-epoxy-morphinanium analogs
CA2718943A1 (en) * 2008-03-26 2009-10-01 Alltranz Inc. Abuse deterrent transdermal formulations of opiate agonists and agonist-antagonists
US8829020B2 (en) * 2009-07-16 2014-09-09 Mallinckrodt Llc Compounds and compositions for use in phototherapy and in treatment of ocular neovascular disease and cancers
EP3064199B1 (en) * 2010-04-02 2023-12-20 Buzzz Pharmaceuticals Limited Abuse-deterrent transdermal formulations of opiate agonists and agonist-antagonists

Also Published As

Publication number Publication date
US20180344726A1 (en) 2018-12-06
MX2018006157A (es) 2019-04-04
ES2799516T3 (es) 2020-12-18
EP3377048B1 (en) 2020-04-22
GB201520390D0 (en) 2016-01-06
CN108601747A (zh) 2018-09-28
EP3377048A1 (en) 2018-09-26
WO2017085502A1 (en) 2017-05-26
BR112018009886A2 (pt) 2018-11-13
IL259457A (en) 2018-07-31
CA3005775A1 (en) 2017-05-26
KR20180074797A (ko) 2018-07-03
JP2018534319A (ja) 2018-11-22
SG11201803913RA (en) 2018-06-28

Similar Documents

Publication Publication Date Title
EP1530469B1 (en) Transdermal dosage form comprising an active agent and a salt and free-base form of an antagonist
CA2955247C (en) Abuse deterrent opiod/opiod-antagonist transdermal patch
JP4874523B2 (ja) 不正使用防止機能付きの経皮的オピオイド送給装置
US20080020028A1 (en) Transdermal dosage form comprising an active agent and a salt and a free-base form of an adverse agent
CA2795158C (en) Abuse-deterrent transdermal formulations of opiate agonists and agonist-antagonists
KR102082529B1 (ko) 오피오이드-유도 유해 약역학 반응을 치료하기 위한 시스템 및 방법
US20200276187A1 (en) Systems and methods for attenuating opioid-induced euphoria
EP3377048B1 (en) Abuse resistant transdermal delivery devices and compositions comprising an opioid agonist and a non-transdermally delivered n-oxide derivative of an opioid antagonist for the treatment of pain
US10406154B2 (en) Transdermal dosage form
US9849124B2 (en) Systems and methods for treating an opioid-induced adverse pharmacodynamic response
WO2020009685A1 (en) Transdermal dosage form
WO2020008366A1 (en) Transdermal dosage form

Legal Events

Date Code Title Description
MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application